Adamas Pharmaceuticals Inc represents a commitment to improving the lives of individuals living with chronic neurologic disorders. The company's corporate philosophy revolves around developing novel, targeted therapies that address unmet medical needs in areas such as Parkinson's disease and multiple sclerosis. Adamas Pharmaceuticals Inc aims to provide innovative treatment options that enhance patients' daily functioning and overall well-being. By leveraging their expertise in pharmacology and neurology, the company continues to prioritize scientific rigor, patient-centricity, and partnerships to drive advancements in the field. Adamas Pharmaceuticals Inc strives to make a positive impact on patient care through its dedication to research, innovation, and improving treatment outcomes.

Adamas Pharmaceuticals Inc is primarily present in the United States.

Adamas Pharmaceuticals Inc has achieved several significant milestones. One of the notable milestones is the FDA approval of their flagship product, GOCOVRI, in 2017. GOCOVRI is the first and only medication indicated for the treatment of dyskinesia in patients with Parkinson's disease. Another significant milestone for Adamas Pharmaceuticals Inc was the successful completion of their Phase 3 clinical trials for ADS-5102, a high-dose, extended-release formulation of amantadine. These milestones demonstrate the company's commitment to developing innovative therapies for neurological disorders and improving the lives of patients.

Adamas Pharmaceuticals Inc is a renowned pharmaceutical company specializing in developing and delivering innovative therapies to address chronic disorders. Founded in 2000, Adamas Pharmaceuticals has a rich history of medical advancements and a deep commitment to improving patient lives. With a primary focus on central nervous system disorders, Adamas Pharmaceuticals diligently utilizes cutting-edge technology and scientific expertise to develop novel treatment options. Their notable breakthrough was the introduction of the FDA-approved medication, GOCOVRI, for the treatment of levodopa-induced dyskinesia in Parkinson's disease. With a strong emphasis on research and development, Adamas Pharmaceuticals Inc continues to pave the way for groundbreaking treatments in the medical field.

The main competitors of Adamas Pharmaceuticals Inc in the market include companies such as Biogen Inc, Novartis AG, and Teva Pharmaceutical Industries Ltd. These companies operate in the pharmaceutical industry and may have similar products or focus on similar therapeutic areas as Adamas Pharmaceuticals Inc.

Adamas Pharmaceuticals Inc is primarily active in the healthcare industry.

The business model of Adamas Pharmaceuticals Inc. revolves around developing and commercializing innovative therapeutics to address chronic diseases. Adamas focuses on improving patient outcomes through the discovery and development of novel treatment options. The company leverages its expertise in pharmacology, formulation, and drug delivery to create differentiated products. Adamas Pharmaceuticals Inc. strives to enhance the quality of life for patients by providing effective and accessible therapies. With a commitment to research and development, Adamas Pharmaceuticals Inc. aims to bring valuable treatments to market, thereby contributing to the advancement of healthcare.

مُعامل القيمة السوقية إلى الأرباح لـ Adamas Pharmaceuticals هو ؜-٢٩٫٢٢.

مُعامِل القيمة إلى المبيعات Adamas Pharmaceuticals هو ١٫٤٣.

نقاط جودة AlleAktien لـ Adamas Pharmaceuticals هي 4/10.

المتوقعة Adamas Pharmaceuticals الإيرادات هي ١٦٢٫٤٩ مليون. USD.

صافي الربح المتوقعة Adamas Pharmaceuticals هو ؜-٧٫٩٦ مليون. USD.

Adamas Pharmaceuticals Inc is a US-based company that specializes in the development and marketing of drugs for the treatment of neurological disorders. The company focuses on the treatment of Parkinson's disease and other movement disorders. Adamas has built its business on three pillars: - Product development - Product distribution - Technology licensing The company's key products are the medications GOCOVRI and NAMZARIC, both used for the treatment of Parkinson's disease. GOCOVRI is an extended-release and delayed-release version of the drug amantadine, while NAMZARIC is a combination of two drugs, cholinesterase inhibitors and memantine. GOCOVRI was developed to treat the symptoms of Parkinson's disease in the late phase when normal treatment methods such as dopamine agonists or levodopa are no longer successful. The medication was approved by the FDA in 2017 and is currently being marketed in the USA. Adamas Pharmaceuticals Inc has exclusive rights to GOCOVRI in the USA and Canada. NAMZARIC is another important product of Adamas Pharmaceuticals Inc. It is used for the treatment of moderate to severe dementia in patients with Alzheimer's disease. NAMZARIC contains two active ingredients - cholinesterase inhibitors and memantine - making it a unique medication. The medication was approved by the FDA in 2015. Adamas Pharmaceuticals Inc also has a strong presence in technology licensing. The company has an agreement with Forest Laboratories (now Allergan) for the licensing of intellectual property to manufacture Namenda, another medication for Alzheimer's disease. Adamas also has partnerships with other companies such as Osmotica Pharmaceuticals and Neurocrine Biosciences. The collaboration with these companies aims to create synergies and accelerate the development of new medications. The business model of Adamas Pharmaceuticals Inc is based on offering groundbreaking therapeutic solutions. The focus is on developing drugs for the treatment of central nervous system disorders and other neurological conditions. The company leverages its scientific knowledge and expertise to conduct clinical trials, develop innovative therapies, and establish connections with other partners. Overall, Adamas Pharmaceuticals Inc has developed an innovative and successful business model based on the creation of therapeutic solutions. The company has a strong presence in the neurological pharmaceutical industry and is expected to continue growing and thriving while continuing to develop innovative products to help improve patients' quality of life.

يوزع Adamas Pharmaceuticals أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Adamas Pharmaceuticals في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـAdamas Pharmaceuticals هو US00548A1060.

رمز WKN لـ Adamas Pharmaceuticals هو A111X7.

الرمز المُختصر لـ Adamas Pharmaceuticals هو ADMS.

خلال آخر 12 شهراً، دفعت Adamas Pharmaceuticals توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Adamas Pharmaceuticals خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Adamas Pharmaceuticals هي .

Adamas Pharmaceuticals يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Adamas Pharmaceuticals دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Adamas Pharmaceuticals يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من Adamas Pharmaceuticals المُعلن عنها في ٢٦‏/٩‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٦‏/٩‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ٢٦‏/٩‏/٢٠٢٤.

في العام 2023، وزعت Adamas Pharmaceuticals 0 USD كأرباح أسهم.

يتم توزيع أرباح Adamas Pharmaceuticals بالعملة USD.